Quick Answer
ORAMED PHARMACEUTICALS INC. reported Diluted EPS of $1.50 per share for fiscal year 2025.
ORAMED PHARMACEUTICALS INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.50 | +412.5% |
| 2024 | -$0.48 | -442.9% |
| 2023 | $0.14 | +114.9% |
| 2022 | -$0.94 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.13 | +335.4% | +264.5% |
| June 30, 2025 | $0.31 | +40.9% | +263.2% |
| March 31, 2025 | -$0.19 | -575.0% | +60.4% |
| September 30, 2024 | -$0.48 | -500.0% | -318.2% |
| June 30, 2024 | $0.22 | +833.3% | +450.0% |
| March 31, 2024 | $0.04 | +150.0% | +150.0% |
| September 30, 2023 | -$0.08 | -144.4% | -166.7% |
| June 30, 2023 | -$0.03 | -111.1% | +62.5% |
- ORAMED PHARMACEUTICALS INC. showed an increase of +412.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, ORAMED PHARMACEUTICALS INC.’s diluted eps has grown by 259.6% (from $0.94 per share (loss) to $1.50 per share).
- The most recent figure is from ORAMED PHARMACEUTICALS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: